Identification of the patient with enlarged prostate: Diagnosis and guidelines for management

Osteopathic Medicine and Primary Care

Volumn 1, Issue , 2007, Pages

  Kaplan, Steven A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548277545     PISSN: None     EISSN: 17504732     Source Type: Journal    
DOI: 10.1186/1750-4732-1-11     Document Type: Review

References (22)

1. National Institutes of Diabetes and Digestive and Kidney Disease Kidney and Urologic Diseases Statistics for the United States 2006 http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/index.htm
2. Committee AUAPG AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations J Urol 2003 170 530-547 10.1097/01.ju.0000078083.38675.79 12853821
3. Collins MM Barry MJ Bin L Roberts RG Oesterling JE Fowler FJ Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians J Gen Intern Med 1997 12 224-229 1497095 9127226
4. McConnell JD Roehrborn CG Bautista OM Andriole GL Jr. Dixon CM Kusek JW Lepor H McVary KT Nyberg LM Jr. Clarke HS Crawford ED Diokno A Foley JP Foster HE Jacobs SC Kaplan SA Kreder KJ Lieber MM Lucia MS Miller GJ Menon M Milam DF Ramsdell JW Schenkman NS Slawin KM Smith JA Medical Therapy of Prostatic Symptoms (MTOPS) Research Group The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 2003 349 2387-2398 10.1056/NEJMoa030656 14681504
5. Roehrborn CG Boyle P Nickel JC Hoefner K Andriole G and ARIA Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 2002 60 434-441 10.1016/S0090-4295(02)01905-2 12350480
6. Gades NM Jacobson DJ Girman CJ Roberts RO Lieber MM Jacobsen SJ Prevalence of conditions potentially associated with lower urinary tract symptoms in men BJU Int 2005 95 549-553 10.1111/j.1464-410X.2005.05337.x 15705078
7. Issa MM Marshall FF Contemporary diagnosis and management of diseases of the prostate Newtown, Pa, Handbooks in Health Care Co 3rd 2005
8. Kaplan SA Benign Prostatis Hyperplasia and Enlarged Prostate Guidelines: How They Can Be Useful to Primary Care New York, Weill Medical College of New York University Weill Medical College of New York University Reports on Men's Urologic Health 2006 Vol. 1, No. 1
9. Roehrborn CG Accurate determination of prostate size via digital rectal examination and transrectal ultrasound Urology 1998 51 19-22
10. Roberts RO Jacobsen SJ Jacobson DJ Rhodes T Girman CJ Lieber MM Longitudinal changes in peak urinary flow rates in a community based cohort J Urol 2000 163 107-113 10.1016/S0022-5347(05)67984-0 10604326
11. Kawakami J Nickel JC Acute urinary retention and surgery for benign prostatic hyperplasia: The patient's perspective Can J Urol 1999 6 819-822 11178608
12. Choong S Emberton M Acute urinary retention BJU Int 2000 85 186-201 10.1046/j.1464-410x.2000.00409.x 10671867
13. Jacobsen SJ Jacobson DJ Girman CJ Roberts RO Rhodes T Guess HA Lieber MM Natural history of prostatism: Risk factors for acute urinary retention J Urol 1997 158 481-487 10.1016/S0022-5347(01)64508-7 9224329
14. Arrighi HM Metter EJ Guess HA Fozzard JL Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging Urology 1991 38 4-8 10.1016/ 0090-4295(91)80191-9 1714657
15. Djavan B Chapple C Milani S Marberger M State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia Urology 2004 64 1081-1088 10.1016/j.urology.2004.07.031 15596173
16. Clark RV Hermann DJ Cunningham GR Wilson TH Morrill BB Hobbs S Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor J Clin Endocrinol Metab 2004 89 2179-2184 10.1210/jc.2003-030330 15126539
17. Bartsch G Rittmaster RS Klocker H Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia Eur Urol 2000 37 367-380 10.1159/000020181 10765065
18. Andriole GL Kirby R Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia Eur Urol 2003 44 82-88 10.1016/S0302-2838(03)00198-2 12814679
19. Debruyne F Barkin J van Erps P Reis M Tammela TL Roehrborn C and ARIB Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia Eur Urol 2004 46 488-494 10.1016/ j.eururo.2004.05.008 15363566
20. McConnell JD Bruskewitz R Walsh P Andriole G Lieber M Holtgrewe HL Albertsen P Roehrborn CG Nickel JC Wang DZ Taylor AM Waldstreicher J The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group N Engl J Med 1998 338 557-563 10.1056/NEJM199802263380901 9475762
21. Barkin J Guimaraes M Jacobi G Pushkar D Taylor S van Vierssen Trip OB Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride Eur Urol 2003 44 461-466 10.1016/S0302-2838(03)00367-1 14499682
22. Baldwin KC Ginsberg PC Harkaway RC Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction Urol Int 2001 66 84-88 10.1159/000056576 11223749